Generated November 18, 2026 at 8:33 PM ET
· Covers November 18 trading day
· 10 of 179 ready 8-Ks selected
· AI-assisted overview
The day's 8-K filings were led by Palo Alto Networks' Q1 FY27 results, which included raised FY27 guidance and a $4.5B all-stock acquisition of Applied Compute, alongside Textron's definitive agreement to sell its Industrial segment to a Kingswood affiliate for $1.2B cash. Two other deal items appeared: LCI stockholders approved the all-stock merger with Patrick Industries, and Drugs Made In America Acquisition II disclosed a preliminary, nonbinding $600M proposal for Alpha AI Biotech payable in shares. Two companies received Nasdaq stockholders' equity deficiency notices — Passage Bio and MetaVia — with MetaVia facing a January 4, 2027 deadline to submit a compliance plan. Leadership and capital-structure items rounded out the set: Ecovyst's CEO departure with an interim appointment, ChronoScale's $153M common and $500M preferred placements tied to an Odessa data-center joint venture, SPAR Group's note-for-preferred exchange with a new revolver, and Arizona regulatory approval of Tucson Electric Power's rate increase.
leadership
negative
materiality 0.75
November 18, 2026, 6:12 AM ET
Ecovyst CEO Kurt Bitting exits; director David Bradley named interim CEO, FY2026 guidance reaffirmed
- Kurt J. Bitting ceased as President and CEO effective Nov 17, 2026 and resigned from the board, which shrank to seven; Ecovyst said no disagreement prompted the exit.
- David A. Bradley, a director since 2022 and former SI Group CEO from 2019 to October 2026, became interim CEO; Ecovyst has begun a search for a permanent CEO.
- Bradley will receive a $1.1M annual base salary and $2M in restricted stock units vesting at the earlier of a permanent CEO's start or his first anniversary.
M&A
positive
materiality 0.85
November 18, 2026, 7:44 AM ET
Textron to sell Industrial segment (Kautex, Specialized Vehicles) to Kingswood for $1.2B cash
- Definitive agreement with Meridian Buyer LLC, an affiliate of Kingswood Capital Management, for $1.2B cash covering Kautex and Textron Specialized Vehicles (E-Z-GO, Cushman, Jacobsen, Premier).
- Net cash proceeds expected ~$1.1B after tax and transaction expenses; Textron plans additional share repurchases in 2027 funded by the proceeds; deal has no financing contingency.
- Q4 2026 non-cash pre-tax impairment of $350M-$400M, including ~$175M of cumulative foreign-currency translation adjustments; Industrial moves to held-for-sale and discontinued operations.
M&A
positive
materiality 0.75
November 18, 2026, 5:12 PM ET
LCI stockholders approve all-stock merger with Patrick Industries; close expected in H1 2027
- Merger agreement adopted with 20,049,918 votes for, 480,909 against, 29,006 abstaining — roughly 98% of votes cast and 82% of outstanding shares.
- Non-binding advisory compensation (golden parachute) proposal failed: 9,695,102 for vs 10,282,053 against, 582,678 abstaining.
- 24,312,075 LCI shares outstanding as of the Oct. 15, 2026 record date; 20,559,833 represented at the Nov. 18 special meeting, meeting quorum.
DMII
Drugs Made In America Acquisition II Corp.
M&A
positive
materiality 0.70
November 18, 2026, 11:08 AM ET
DMII proposes $600M combination with Alpha AI Biotech paid in 60M shares at $10.00
- Preliminary, nonbinding proposal values Alpha AI Biotech Group at $600 million pre-money, payable in 60,000,000 ordinary shares at $10.00 per share.
- Up to 30,000,000 additional earn-out shares in two equal tranches tied to share-price thresholds of $12.50 and $15.00 during 24 months after closing.
- Board approved a 30-day limited standstill expiring on or about December 3, 2026; no definitive agreement, due diligence and audited financials still pending.
regulatory
negative
materiality 0.62
November 18, 2026, 4:15 PM ET
Passage Bio gets Nasdaq deficiency notice; stockholders' equity $50K vs $2.5M minimum
- Nasdaq Rule 5550(b)(1) requires $2.5M minimum stockholders' equity; Passage Bio reported $50,000 at Sept 30, 2026 and fails the market-value and net-income alternatives.
- Letter from Nasdaq Listing Qualifications dated Nov 12, 2026 has no immediate effect; PASG continues trading on the Nasdaq Capital Market.
- Company expects the pending Remix Therapeutics mergers (A&R agreement dated Sept 2, 2026, amended Oct 5, 2026) to restore compliance on close.
regulatory
negative
materiality 0.62
November 18, 2026, 9:01 AM ET
MetaVia gets Nasdaq notice as stockholders' equity falls below $2.5M; plan due by Jan 4, 2027
- Nasdaq notice dated Nov 17, 2026 cites violation of Listing Rule 5550(b)(1): stockholders' equity below the $2.5M minimum as of the Sept 30, 2026 Form 10-Q.
- Company also fails the alternative compliance standards under Nasdaq continued-listing rules.
- MetaVia has 45 calendar days, until January 4, 2027, to submit a plan to regain compliance; Nasdaq may extend up to 180 days from the notice date if it accepts.
PANW
Palo Alto Networks Inc
earnings
positive
materiality 0.92
November 18, 2026, 4:37 PM ET
Palo Alto Networks Q1 FY27 revenue $3.44B (+39%), raises FY27 guide; to buy Applied Compute for $4.5B in stock
- Q1 FY27 revenue $3.44B (+39% YoY); non-GAAP EPS $1.05 vs $0.93; GAAP net income $482M ($0.57/diluted share) vs $334M ($0.47).
- NGS ARR $9.73B (+66% YoY); RPO $21.0B (+35%); non-GAAP operating income $1.1B vs $746M; adjusted free cash flow margin 56.2%.
- FY27 guidance raised: revenue $14.52-14.57B (+26-27%), non-GAAP EPS $4.26-4.30, NGS ARR $11.475-11.525B, non-GAAP operating margin 29.5%.
—
TUCSON ELECTRIC POWER CO
regulatory
positive
materiality 0.60
November 18, 2026, 5:25 PM ET
Arizona regulators approve TEP rate hike: $119M net retail revenue, 9.4% residential bill increase
- ACC approved new rates on Nov. 17, 2026, effective Dec. 1, 2026; average residential bill rises about 9.4%, or ~$13/month, to roughly $150.
- Net +$119M retail revenue: +$165M non-fuel, -$26M fuel-related, -$18M from adjustor mechanism changes, -$2M from lower service fees.
- Allowed 7.12% return on $4.3B original-cost rate base; ROE 9.40%, average cost of debt 4.28%; 55% equity / 45% debt capital structure.
CHRN
EKSO BIONICS HOLDINGS, INC.
other material
positive
materiality 0.97
November 18, 2026, 8:15 AM ET
ChronoScale signs $153M common and $500M preferred placements, forms Odessa data-center JV with STN
- ChronoScale priced a $153.0M common stock private placement at $8.00 per share for about 19.1M shares, expected to close Nov. 18, 2026.
- It also secured a $500M Series C preferred stock purchase agreement, starting with a $10.0M initial put; Goldman Sachs is lead placement agent.
- ChronoScale will fund a $220M convertible note to the OD1 JV; $200M goes to Super Micro Computer for GPUs and $20M to the Partnership.
debt
neutral
materiality 0.75
November 18, 2026, 8:14 AM ET
SPAR Group exchanges $4.0M note, 8.9M shares for Series C preferred; adds $1.5M TRAK revolver
- PC Group exchanged ~$4.0M SPAR promissory note for Series C Preferred at $1,000 stated value; 8,900,406 SPAR shares exchanged for 3,360 preferred, valued at $3,359,605.
- Series C converts at $0.38/share, pays 8% cumulative quarterly dividends (10% if paid in preferred), is senior to all equity, and votes as-converted subject to a 50% ownership cap.
- Warrant covers 9,684,211 common shares at $0.38, exercisable Jan. 31, 2028 through Jan. 31, 2032; TRAK also gets anti-dilution preferred to maintain its percentage.